PFNX - Pfenex Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
5.45
+0.03 (+0.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.42
Open5.30
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.10 - 5.69
52 Week Range2.07 - 6.77
Volume40,742
Avg. Volume116,307
Market Cap128.531M
Beta1.78
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • Reuters2 days ago

    BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo

    April 18 (Reuters) - China NT Pharma Group Co Ltd: * PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO® * PFENEX INC - PFENEX ...

  • PR Newswire2 days ago

    Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo®

    SAN DIEGO and HONG KONG, April 18, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX) and China NT Pharma Group Company Limited (NT Pharma) (1011.HK) today announced an agreement under which Pfenex granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Company's Forteo®, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand. In accordance with the agreement, Pfenex received a payment of $2.5 million upon signing of the agreement and may be eligible to receive additional payments of up to $22.5 million based on the achievement of certain development, regulatory, and sales-related milestones.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of PFNX earnings conference call or presentation 15-Mar-18 8:30pm GMT

    Q4 2017 Pfenex Inc Earnings Call

  • PR Newswirelast month

    Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update

    SAN DIEGO , March 15, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology ® ...

  • ACCESSWIRElast month

    Pfenex, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Pfenex, Inc. (NYSE American: PFNX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern Time. ...

  • One Thing To Consider Before Buying Pfenex Inc (NYSEMKT:PFNX)
    Simply Wall St.last month

    One Thing To Consider Before Buying Pfenex Inc (NYSEMKT:PFNX)

    If you are looking to invest in Pfenex Inc’s (AMEX:PFNX), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • PR Newswirelast month

    Pfenex Inc. to Present at Oppenheimer's 28th Annual Healthcare Conference

    SAN DIEGO , March 13, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that the company will present at Oppenheimer's 28th Annual Healthcare Conference in New York City . President ...

  • PR Newswirelast month

    Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018

    SAN DIEGO , March 8, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its fourth quarter and full year 2017 financial results will be released on Thursday, March 15, 2018 , after ...

  • PR Newswire2 months ago

    Pfenex Inc. to Present at Barclay's 2018 Global Healthcare Conference

    SAN DIEGO , Feb. 27, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that the company will present at Barclay's 2018 Global Healthcare Conference in Miami Beach, Florida . President ...

  • PR Newswire4 months ago

    Pfenex Names Susan A. Knudson as Chief Financial Officer

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) today announced the appointment of Susan A. Knudson as Chief Financial Officer, effective February 1, 2018. "After a thorough search, we are pleased to welcome Susan to the Pfenex team as our Chief Financial Officer," said Eef Schimmelpennink, Chief Executive Officer of Pfenex. Ms. Knudson most recently served as the Chief Financial Officer of Neothetics, Inc., a specialty pharmaceutical company, where she led the company's strategic and corporate finance activities.  Prior to her role at Neothetics, Ms. Knudson served as Senior Director of Finance and Administration at Avera Pharmaceuticals, where she drove financing strategy, and was an integral part of the business development team interacting with multinational pharmaceutical companies.

  • PR Newswire4 months ago

    Pfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz Pharmaceuticals

    SAN DIEGO, Dec. 19, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX) today announced the amendment of the 2016 agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. Under the amended agreement, Pfenex will be eligible to receive an additional $43.5 million in amendment fee and development milestone payments as compared to the 2016 agreement, increasing the total value of upfront, option and amendment fee payments and potential payments for the achievement of development, regulatory and sales-related milestones associated with the collaboration to an aggregate of $224.5 million.  Pfenex will also continue to be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration, at rates reduced from those under the 2016 agreement.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of PFNX earnings conference call or presentation 9-Nov-17 9:30pm GMT

    Q3 2017 Pfenex Inc Earnings Call

  • PR Newswire5 months ago

    Pfenex Inc. to Present at the Jefferies 2017 London Healthcare Conference

    SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that it will be presenting at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15 th at ...

  • Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update
    PR Newswire5 months ago

    Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update

    SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage biotechnology company developing complex therapeutic proteins. Using the patented Pfenex Expression Technology ...

  • ACCESSWIRE5 months ago

    Pfenex, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Pfenex, Inc. (NYSE: PFNX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 4:30 PM Eastern Time. To ...

  • PR Newswire6 months ago

    Pfenex to Report Third Quarter 2017 Results and Provide Business Update on Thursday, November 9, 2017

    SAN DIEGO , Oct. 30, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its third quarter 2017 financial results will be released on Thursday, November 9, 2017 , after the market close. ...

  • Capital Cube6 months ago

    ETFs with exposure to Pfênex, Inc. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfênex, Inc. Here are 5 ETFs with the largest exposure to PFNX-US. Comparing the performance and risk of Pfênex, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Pfênex, Inc. :PFNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
    Capital Cube7 months ago

    Pfênex, Inc. :PFNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017

    Categories: Yahoo FinanceGet free summary analysis Pfênex, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Pfênex, Inc. – China Biologic Products Holdings, Inc., Genocea Biosciences, Inc., Affimed N.V. and Epizyme, Inc. (CBPO-US, GNCA-US, AFMD-US and EPZM-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • PR Newswire7 months ago

    Pfenex To Present at the Cantor Fitzgerald Global Healthcare Conference on September 27th, 2017

    SAN DIEGO , Sept. 19, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the Cantor Fitzgerald Global Healthcare Conference on September 27 th , 2017 at 4:00 ...

  • PR Newswire7 months ago

    Pfenex Announces Management Changes

    SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), today announced that Dr. Paul Wagner, Chief Financial Officer, is leaving the Company effective October 13, 2017 to assume another position in industry. Pfenex is conducting an executive search for a replacement CFO. Additionally, Steve Sandoval, Chief Manufacturing Officer, is leaving the Company effective September 8, 2017, to pursue other opportunities.

  • PR Newswire8 months ago

    Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules

    SAN DIEGO, Sept. 1, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) ("Pfenex" or the "Company"), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high-value and difficult to manufacture proteins, today reported, as required by the NYSE MKT Company Guide, an equity inducement award to Eef Schimmelpennink, the Company's new Chief Executive Officer, President, and Secretary, who officially commenced employment with the Company on August 3, 2017. The stock option was granted to Mr. Schimmelpennink pursuant to the Pfenex Inc. 2016 Inducement Equity Incentive Plan, which was approved by the Company's board of directors under Rule 711(a) and the other relevant rules of the NYSE MKT Company Guide for equity grants to induce new employees to enter into employment with the Company.

  • PR Newswire8 months ago

    Pfenex To Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12th, 2017

    SAN DIEGO , Aug. 29, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the 19 th Annual Rodman and Renshaw Global Investment Conference on September 12 th ...